Integrated evolutionary analysis reveals antimicrobial peptides with limited resistance

Area of Science:

• Microbiology
• Molecular Biology
• Drug Discovery

Background:

• Antimicrobial peptides (AMPs) represent a promising class of therapeutics.
• Bacterial resistance to AMPs is a significant concern, potentially limiting their clinical utility.
• Understanding the mechanisms and limitations of AMP resistance is crucial for developing effective antimicrobial strategies.

Purpose of the Study:

• To systematically investigate the evolution of bacterial resistance to a diverse set of AMPs and antibiotics in Escherichia coli.
• To identify specific AMPs that exhibit limited resistance evolution.
• To explore the role of physicochemical properties in dictating bacterial resistance to AMPs.

Main Methods:

• Experimental evolution of Escherichia coli resistance to 14 chemically diverse AMPs and 12 antibiotics.
• Genomic analysis to identify mutations and gene amplifications conferring resistance.
• Introduction of genomic fragments from soil bacteria into E. coli to assess resistance transfer.

Main Results:

• Resistance evolution was limited for certain AMPs, including tachyplesin II and cecropin P1.
• Low levels of resistance were observed via point mutations and gene amplification.
• Antibiotic-resistant bacteria showed no cross-resistance to these specific AMPs.
• Genomic fragments conferring resistance to AMPs were not detected.
• Physicochemical properties of AMPs were found to correlate with the propensity for resistance evolution.

Conclusions:

• Certain AMPs demonstrate a reduced capacity for bacterial resistance evolution compared to conventional antibiotics.
• The findings suggest that AMPs with specific physicochemical characteristics may be valuable for developing novel therapeutics with lower resistance potential.
• This research provides a foundation for designing next-generation AMP-based drugs that are less susceptible to resistance, preserving innate immune system function.